Eli Lilly’s Trulicity’s Broad CV Label Spotlights GLP-1 Rivalry

Direct Impact On Novo Nordisk’s Ozempic ‘Limited’

 
• By Sten Stovall

Trulicity’s broad CV label awarded by the US FDA should aid overall uptake of the GLP-1 class, cushioning the direct impact on Novo Nordisk’s rival, Ozempic, analysts said.

Doctor_Heart
Trulicity is first type 2 diabetes drug approved to cut CV events in adults with and without heart disease. • Source: Shutterstock

More from Business

More from Scrip